Pulmonary Arterial Pressure Response During Exercise (PAPCOPDHS)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
The extent of increase in systolic pulmonary arterial pressure (PAPs) during exercise in patients with COPD is unpredictable from lung function data. The non-invasive assessment of pulmonary hemodynamics during exercise and flow-mediated vasodilatation measurement may give useful data in the rehabilitation of COPD patients.
Methods:
Patients with stable, severe COPD and healthy, age-matched subjects (H) perform semi supine echocardiography with PAPs measurement. COPD patients perform ramp protocol with gas exchange detection. Serum hsCRP level is also determined in COPD patients. Endothel dysfunction is detected by flow mediated vasodilation measurement after arm strangulation with Doppler ultrasonography.
Primary endpoint:
The degree of pulmonary artery systolic pressure change during exercise?
Secondary endpoint:
- The degree of right ventricular function change during exercise?
- Is endothel dysfunction manifested with pulmonary artery pressure rise?
- What is the correlation between the systemic inflammatory marker hsCRP and the degree of pulmonary artery pressure rise?
| Condition | Intervention |
|---|---|
|
COPD Patients Healthy Subjects Semi-supine Echo (SSE) Flow-mediated Vasodilatation (FMD) High Sensitive C-reactive Protein (hsCRP) |
Other: Measure pulmonary artery pressure change during exercise Other: Pulmonary pressure response during exercise |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Pulmonary Arterial Pressure Response During Exercise in COPD and Healthy Subjects |
- The degree of pulmonary artery pressure change during exercise? [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]
- Right ventricular function change? Correlation between systemic inflammation (hsCRP) and pulmonary artery pressure change? Endothelial dysfunction? [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: None Retained
Blood sample is taken to analyse the systemic inflammatory marker (hsCRP) level from serum. We measure the samples and than we don't store it.
| Estimated Enrollment: | 80 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
COPD patients
COPD patients with severe obstruction performed the tests.
|
Other: Measure pulmonary artery pressure change during exercise
Semi-supine echocardiography test
Other Name: lung function, CPX, HsCRP
Other: Pulmonary pressure response during exercise
Semi-supine echocardiography test
Other Name: Complete lung function, CPX, HsCRP
|
|
Healthy subjects
Age-matched healthy subjects performed the same test also.
|
Other: Measure pulmonary artery pressure change during exercise
Semi-supine echocardiography test
Other Name: lung function, CPX, HsCRP
Other: Pulmonary pressure response during exercise
Semi-supine echocardiography test
Other Name: Complete lung function, CPX, HsCRP
|
Detailed Description:
Background: The extent of increase in systolic pulmonary arterial pressure (PAPs) during exercise in patients with COPD is unpredictable from lung function data. The non-invasive assessment of pulmonary hemodynamics during exercise by semi-supine echocardiography and flow-mediated vasodilatation measurement may give useful data in the rehabilitation of COPD patients.
Methods: Patients with stable, severe COPD and healthy, age-matched subjects (H) perform semi supine echocardiography with PAPs measurement. COPD patients perform ramp protocol with gas exchange detection. Serum hsCRP level is also determined in COPD patients. All of the subjects perform complete lung function with body pletysmography and diffusion capacity measurement. Endothel dysfunction is detected by flow mediated vasodilation measurement after arm strangulation with Doppler ultrasonography.
Eligibility| Ages Eligible for Study: | 45 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
COPD patients (age between 45 and 70) with moderate to severe obstruction (FEV1<60%) and healthy subjects (age between 45 and 70)
Inclusion Criteria:
- COPD patients (age between 45 and 70)
- with moderate to severe obstruction (FEV1<60%pred) and
- healthy subjects (age between 45 and 70, (FEV1>80%pred, FEV1/FVC>70%
Exclusion Criteria:
- Not in the age range
- Different FEV1 value
- Severe comorbidities
Contacts and Locations| Contact: Attila Somfay, MD, PhD | +36-62-571-551 | somfay@deszk.szote.u-szeged.hu |
| Contact: Janos Varga, MD | +36-62-571-527, +36209204235 | janosvargaster@gmail.com |
| Hungary | |
| Department of Pulmonology, Szeged University | Recruiting |
| Deszk, Csongrad County, Hungary, 6772 | |
| Contact: Attila Somfay, MD, PhD +36-62-571-552 somfay@deszk.szote.u-szeged.hu | |
| Contact: Janos Varga, MD +36-62-571-527, +36209204235 janosvargaster@gmail.com | |
| Principal Investigator: Attila Somfay, MD, PhD | |
| Sub-Investigator: Janos Varga, MD | |
| Sub-Investigator: Imre Lajko, MD | |
| Principal Investigator: | Attila Somfay, MD, PhD | Department of Pulmonology, Szeged University |
More Information
No publications provided
| Responsible Party: | Attila Somfay, MD, PhD; Department Leader, Department of Pulmonology, Szeged University |
| ClinicalTrials.gov Identifier: | NCT00949195 History of Changes |
| Other Study ID Numbers: | SZTE PULM-PAHP, ISRCTN11034505 |
| Study First Received: | July 29, 2009 |
| Last Updated: | July 20, 2011 |
| Health Authority: | Hungary: National Institute of Pharmacy |
Keywords provided by Szeged University:
|
COPD healthy patients PAP CPX |
SSE hsCRP FMD |
Additional relevant MeSH terms:
|
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on June 13, 2013